CRIS

Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1

Browse

Settings

Has files: NoSubject: search.filters.subject.oncology

Search Results

Now showing 1 - 8 of 8
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Latin America Cutaneous Oncology Management (LACOM) I: The Role of Skin Care in Oncology Patients and Survivors
    (SanovaWorks, 2025-02-01)
    Daniel Alcalá Pérez
    ;
    Ana Sofia Acosta Madiedo
    ;
    Sebastian Andreani
    ;
    Anneke Andriessen
    ;
    Hebert Cárdenas
      2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Effects on Quality of Life of a Telemonitoring Platform amongst Patients with Cancer (EQUALITE): A Randomized Trial Protocol
    (2024)
    Felipe Martínez
    ;
    Carla Taramasco
    ;
    Manuel Espinoza
    ;
    ACEVEDO ROMO, JOHANNA PATRICIA  
    ;
    Carolina Goic
    <jats:p>Cancer, a pervasive global health challenge, necessitates chemotherapy or radiotherapy treatments for many prevalent forms. However, traditional follow-up approaches encounter limitations, exacerbated by the recent COVID-19 pandemic. Consequently, telemonitoring has emerged as a promising solution, although its clinical implementation lacks comprehensive evidence. This report depicts the methodology of a randomized trial which aims to investigate whether leveraging a smartphone app called Contigo for disease monitoring enhances self-reported quality of life among patients with various solid cancers compared to standard care. Secondary objectives encompass evaluating the app’s impact on depressive symptoms and assessing adherence to in-person appointments. Randomization will be performed independently using an allocation sequence that will be kept concealed from clinical investigators. Contigo offers two primary functions: monitoring cancer patients’ progress and providing educational content to assist patients in managing common clinical situations related to their disease. The study will assess outcomes such as quality of life changes and depressive symptom development using validated scales, and adherence to in-person appointments. Specific scales include the EuroQol Group’s EQ-5D questionnaire and the Patient Health Questionnaire (PHQ-9). We hypothesize that the use of Contigo will assist and empower patients receiving cancer treatment, which will translate to better quality of life scores and a reduced incidence of depressive symptoms. All analyses will be undertaken with the intention-to-treat principle by a statistician unaware of treatment allocation. This trial is registered in ClinicalTrials under the registration number NCT06086990.</jats:p>
    Scopus© Citations 2  2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Treatments for non-small cell lung cancer: a systematic quality assessment of clinical practice guidelines
    (2023)
    Marcela Cortés-Jofré
    ;
    Meisser Madera
    ;
    Lesbia Tirado-Amador
    ;
    Claudia Asenjo-Lobos  
    ;
    Xavier Bonfill-Cosp
      4Scopus© Citations 3
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Cardiovascular Assessment Tool for Breast Cancer Survivors and Oncology Providers: Usability Study
    (2021)
    Kathryn E Weaver
    ;
    Heidi D Klepin
    ;
    Brian J Wells
    ;
    Emily V Dressler
    ;
    Karen M Winkfield
    <jats:sec> <jats:title>Background</jats:title> <jats:p>Cardiovascular health is of increasing concern to breast cancer survivors and their health care providers, as many survivors are more likely to die from cardiovascular disease than cancer. Implementing clinical decision support tools to address cardiovascular risk factor awareness in the oncology setting may enhance survivors’ attainment or maintenance of cardiovascular health.</jats:p> </jats:sec> <jats:sec> <jats:title>Objective</jats:title> <jats:p>We sought to evaluate survivors’ awareness of cardiovascular risk factors and examine the usability of a novel electronic health record enabled cardiovascular health tool from the perspective of both breast cancer survivors and oncology providers.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Breast cancer survivors (n=49) recruited from a survivorship clinic interacted with the cardiovascular health tool and completed pre and posttool assessments about cardiovascular health knowledge and perceptions of the tool. Oncologists, physician assistants, and nurse practitioners (n=20) who provide care to survivors also viewed the cardiovascular health tool and completed assessments of perceived usability and acceptability.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Enrolled breast cancer survivors (84% White race, 4% Hispanic ethnicity) had been diagnosed 10.8 years ago (SD 6.0) with American Joint Committee on Cancer stage 0, I, or II (45/49, 92%). Prior to viewing the tool, 65% of survivors (32/49) reported not knowing their level for one or more cardiovascular health factors (range 0-4). On average, only 45% (range 0%-86%) of survivors’ known cardiovascular health factors were at an ideal level. More than 50% of survivors had ideal smoking status (45/48, 94%) or blood glucose level (29/45, 64%); meanwhile, less than 50% had ideal blood pressure (12/49, 24%), body mass index (12/49, 24%), cholesterol level (17/35, 49%), diet (7/49, 14%), and physical activity (10/49. 20%). More than 90% of survivors thought the tool was easy to understand (46/47, 98%), improved their understanding (43/47, 91%), and was helpful (45/47, 96%); overall, 94% (44/47 survivors) liked the tool. A majority of survivors (44/47, 94%) thought oncologists should discuss cardiovascular health during survivorship care. Most (12/20, 60%) oncology providers (female: 12/20, 60%; physicians: 14/20, 70%) had been practicing for more than 5 years. Most providers agreed the tool provided useful information (18/20, 90%), would help their effectiveness (18/20, 90%), was easy to use (20/20, 100%), and presented information in a useful format (19/20, 95%); and 85% of providers (17/20) reported they would use the tool most or all of the time when providing survivorship care.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>These usability data demonstrate acceptability of a cardiovascular health clinical decision support tool in oncology practices. Oncology providers and breast cancer survivors would likely value the integration of such apps in survivorship care. By increasing awareness and communication regarding cardiovascular health, electronic health record–enabled tools may improve survivorship care delivery for breast cancer and ultimately patient outcomes.</jats:p> </jats:sec>
      10Scopus© Citations 10
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Updated clinical practice recommendations for managing children with 22q11.2 deletion syndrome
    (2023)
    Sólveig Óskarsdóttir
    ;
    Erik Boot
    ;
    Terrence Blaine Crowley
    ;
    Joanne C.Y. Loo
    ;
    Jill M. Arganbright
    Scopus© Citations 50  2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Concordance Analysis of ALK Gene Fusion Detection Methods in Patients with Non–Small-Cell Lung Cancer from Chile, Brazil, and Peru
    (2021)
    Gonzalo Sepúlveda-Hermosilla
    ;
    Matías Freire
    ;
    Alejandro Blanco
    ;
    Javier Cáceres
    ;
    Rodrigo Lizana
      1Scopus© Citations 6
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Regionalización de la Cirugía Oncológica Torácica en Chile
    (2021)
    Pablo Perez
    ;
    Raimundo Santolaya
    ;
    Raul Berrios
    ;
    Jose Ortega
    ;
    Manfred Zink
    <jats:p>La patología oncológica representa la segunda causa de muerte en Chile. Si bien se han realizado importantes avances como las garantías explicitas de salud para 17 patologías malignas, la Ley Ricarte Soto para enfermedades de alto costo y la Ley del Cáncer Dr. Claudio Mora, aun existen importantes diferencias de sobrevida basados en estrato socioeconómico y desgraciadamente no existen datos nacionales sobre diferencias en resultados clínicos entre centros de alto y bajo volumen. Para avanzar en un cuidado de pacientes con cáncer que permita a la población de Chile recibir una buena atención y optar a los mejores resultados oncológicos posibles, se hace necesario concentrar la experiencia en cáncer en un grupo mas reducido de centros regionales que puedan concentrar recursos y experiencia.</jats:p>
      17
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
      2Scopus© Citations 1